Continuous Positive Airway Pressure and Cardiometabolic Risk
Children with sleep disordered breathing will benefit from treatment with Continuous Positive Airway Pressure (CPAP) or Bi-level Positive Airway Pressure (BiPAP) in terms of reduction in cardiovascular risk markers and insulin resistance.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Health Services Research
|Official Title:||Impact of Treatment of Sleep Disordered Breathing With Continuous Positive Airway Pressure (CPAP)on Cardiometabolic Risk Markers|
- To determine the impact of treatment of SDB with Continuous Positive Airway Pressure (CPAP) or Bi-level Positive Airway Pressure (BiPAP) on cardiometabolic risk markers [ Time Frame: 12-16 weeks ] [ Designated as safety issue: No ]Labs tests including insulin, insulin resistance and oxidative stress markers.
- To determine the impact of treatment of SDB with CPAP or BiPAP on proinflammatory and anti-inflammatory cytokines [ Time Frame: 12-16 weeks. ] [ Designated as safety issue: No ]
|Study Start Date:||March 2011|
|Study Completion Date:||January 2013|
|Primary Completion Date:||January 2013 (Final data collection date for primary outcome measure)|
CPAP for three months
Continuous Airway Positive Airway Pressure for three months
Obese children with Moderate to Severe Sleep Apnea would have baseline evaluation of markers of cardiometabolic risk and insulin resistance. Subjects will then use CPAP for 3 months and will return for another blood draw for measurement of the markers for cardiometabolic risk and insulin resistance.